Faculty, Staff and Student Publications
Publication Date
10-27-2022
Journal
Journal of Medicinal Chemistry
Abstract
Cancers harboring homozygous deletion of the glycolytic enzyme enolase 1 (ENO1) are selectively vulnerable to inhibition of the paralogous isoform, enolase 2 (ENO2). A previous work described the sustained tumor regression activities of a substrate-competitive phosphonate inhibitor of ENO2, 1-hydroxy-2-oxopiperidin-3-yl phosphonate (HEX) (5), and its bis-pivaloyoxymethyl prodrug, POMHEX (6), in an ENO1-deleted intracranial orthotopic xenograft model of glioblastoma [Nature Metabolism 2020, 2, 1423-1426]. Due to poor pharmacokinetics of bis-ester prodrugs, this study was undertaken to identify potential non-esterase prodrugs for further development. Whereas phosphonoamidate esters were efficiently bioactivated in ENO1-deleted glioma cells, McGuigan prodrugs were not. Other strategies, including cycloSal and lipid prodrugs of 5, exhibited low micromolar IC50 values in ENO1-deleted glioma cells and improved stability in human serum over 6. The activity of select prodrugs was also probed using the NCI-60 cell line screen, supporting its use to examine the relationship between prodrugs and cell line-dependent bioactivation.
Keywords
Humans, Prodrugs, Organophosphonates, Homozygote, Sequence Deletion, Phosphopyruvate Hydratase, Glioblastoma, Glioma, Esters, Lipids, DNA-Binding Proteins, Biomarkers, Tumor, Tumor Suppressor Proteins
DOI
10.1021/acs.jmedchem.2c01039
PMID
36251833
PMCID
PMC9620261
PubMedCentral® Posted Date
October 2022
PubMedCentral® Full Text Version
Post-print